tLTs form within numerous types of chronic inflammatory lesions (
Aloisi and Pujol-Borrell, 2006) and have been shown to function like secondary lymphoid tissues in the induction of effector B and T cells (
Lee et al., 2006;
Moyron-Quiroz et al., 2006;
Nasr et al., 2007). These inducible tissues can provide protection to virus infection in the absence of LNs or aggravate inflammatory disease. Therefore, in the latter context, it has been suggested that the formation of tLTs may be blocked as a strategy to prevent or mitigate inflammatory disease. The development of LNs and PPs in the fetus (
Eberl et al., 2004), and of ILFs in the intestinal lamina propria (
Eberl and Littman, 2004), requires RORγt
+ LTi cells, and in the absence of RORγt, these lymphoid tissues do not develop. RORγt is also required to generate the proinflammatory Th17 cells (
Ivanov et al., 2006) and IL-22–producing NKp46
+ innate lymphoid cells (
Satoh-Takayama et al., 2008;
Luci et al., 2009). Thus, it has been suggested that RORγt antagonists may be developed to block excessive immunity and chronic inflammation in several pathological settings. However, the role of RORγt
+ LTi cells in the formation of tLTs during inflammation remained to be clearly assessed, and the effect of an absence of functional RORγt, which is involved in the generation of both lymphoid tissues and Th17 cells, must be carefully measured during inflammatory disease.
We find that during colitis induced by DSS, mature colonic tLTs develop that consist of a well structured B cell follicle containing predominantly IgM
+ B cells and a germinal center. Similar tLTs termed iBALTs were reported in influenza A–infected lungs (
Moyron-Quiroz et al., 2004). In the absence of LTi cells in RORγt-deficient mice, both iBALT and colonic tLTs develop, indicating that other cells can take over the function of LTi cells for the induction of lymphoid tissues. In the case of tLTs induced in the pancreas of aged NOD mice, the LTi function is taken over by autoreactive T cells (
Lee et al., 2006). Central to the development of LNs, PPs, and ILFs is LTβR-mediated activation of stromal cells by LTα
1β
2-expressing LTi cells (
Mebius, 2003). Activated stromal cells produce the structural chemokines CC19, CCL21, and CXCL13, which are involved in the recruitment and organization of lymphocytes and DCs (
Dejardin et al., 2002). In the inflamed pancreas, T cells induce the formation of tLTs through the alternative LTβR ligand LIGHT (
Lee et al., 2006). The formation of iBALTs is independent of LTα (
Moyron-Quiroz et al., 2004), and the involvement of LIGHT remains to be assessed. In the case of DSS-induced colonic tLTs, B cells perform the LTi function through LTβ, and thus, presumably, through its membrane-bound LTα
1β
2 heterotrimer. Together, these data show that tLTs can develop during chronic inflammation through similar mechanisms but distinct lymphocyte or lymphoid cell subsets.
We show that the formation of tLTs in RORγt-deficient mice is induced by microbiota through the LTi function of B cells, even though we do not formally exclude an LTi function for other cell types in that context. So how does microbiota induce the recruitment of LTβ
+ B cells? We had shown previously that CCL20 was required for the recruitment of B cells and the formation of ILFs (
Bouskra et al., 2008) but expression of CCL20 was undetectable in RORγt-deficient mice. The only cytokine found to be increased in RORγt-deficient mice treated with DSS was IFN-γ; however, blocking IFN-γ with neutralizing antibody had no effect on the number of tLTs and the severity of disease. The intestine of DSS-treated RORγt-deficient mice nevertheless showed an important infiltration of IgG
+ B cells. We therefore suggest that the microbiota-induced inflammation unfolding in DSS-treated RORγt-deficient mice eventually leads to the sustained recruitment of B cells, which induce the formation of tLTs through their expression of LTα
1β
2. Given that tLTs are primarily B cell follicles, this pathway can generate a positive-feedback loop in B cell activation and differentiation and in the formation of tLTs.
In RORγt-deficient mice during steady state or that have been exposed to DSS, a vast network of tLTs develops that contains approximately three times the number of tLTs found in wild-type mice subjected to the same treatments. RORγt is required for the development of LNs and PPs, as well as for the generation of a collection of lymphoid cells producing IL-17 and/or IL-22, such as Th17 cells and IL-22
+ NKp46
+ cells. The latter cell type was recently shown to be involved in protection against infection by
Citrobacter rodentium and DSS-induced colitis (
Satoh-Takayama et al., 2008), and IL-17 and IL-22 synergize in the activation of epithelial cells to produce antibacterial peptides (
Liang et al., 2006). Thus, it might be expected that the absence of lymphoid tissues and of IL-17/22–producing lymphoid cells in RORγt-deficient will be matched by the increased activity in other immune compartments, such as tLT formation, to maintain a similar level of containment of the intestinal microbiota. Such a compensatory mechanism has been reported by
Lorenz et al. (2003); the inhibition of development of secondary lymphoid tissues through the administration of LTβR-Ig protein to pregnant mothers induced the formation of numerous tLTs or ILFs. However, when exposed to DSS, which injures the epithelial cell layer, RORγt-deficient mice appear only to be able to contain microbiota at the price of an additional increase in intestinal tLTs and B cell activity. This increase in the number of tLTs and in B cell activity is, however, not tolerated by the intestine, which develops severe inflammation and leads the host to wasting disease. This pathology is possibly a consequence of the formation of immune complexes consisting of bacteria and specific IgG, which activate IgG receptor-bearing inflammatory cells, such as neutrophils. This hypothesis is supported by the antiinflammatory effect of IVIG treatment, which is shown to depend on IgG receptors (
Nimmerjahn and Ravetch, 2008).
RORγt controls the proinflammatory IL-17 pathway (
Ivanov et al., 2006), which is shown to be involved in autoimmune pathology through the recruitment of neutrophils (
Weaver et al., 2006). The IL-17/23 pathway is involved in several colitis models in mice (
Uhlig and Powrie, 2009), and patients with a defective IL-23R show resistance to the development of the disease (
Duerr et al., 2006). Therefore, it can be expected that the absence of RORγt, or antagonizing RORγt function during the initial phase of inflammation, protects from progression to inflammatory disease. We show that colitis induced by exposure to DSS was actually more severe in RORγt-deficient mice as compared with RORγt-sufficient mice. In the absence of RORγt, the colon developed profound tissue damage, and mice suffered from marked wasting disease, whereas in the presence of RORγt, mice endured mild intestinal inflammation under the regimen applied and grew normally. Furthermore, complementation of RORγt-deficient mice with RORγt-sufficient spleen cells significantly decreased the severity of the disease, demonstrating a protective effect of RORγt
+ cells in intestinal pathology. We suggest that RORγt
+ cells, including Th17 cells and IL-22–producing NKp46
+ cells, limit DSS-induced intestinal inflammatory disease by strengthening antibacterial immunity, such as the production of antibacterial peptides by epithelial cells (
Liang et al., 2006). Thus, our data show that a narrow road has to be followed to prevent the pathological effect of immunity during colitis while maintaining the essential functions of immunity for intestinal homeostasis and defense.